Free Trial

TG Therapeutics (TGTX) News Today

TG Therapeutics logo
$35.24 +0.67 (+1.94%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$35.12 -0.12 (-0.33%)
As of 04:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TGTX Latest News

TG Therapeutics, Inc. stock logo
Bank of America Corp DE Has $6.95 Million Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)
Bank of America Corp DE cut its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 86.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 230,939 shares of the biopharmaceutical comp
TG Therapeutics, Inc. stock logo
Connecticut Wealth Management LLC Sells 13,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)
Connecticut Wealth Management LLC lessened its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 46.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,782 shares of the biopharmace
TG Therapeutics, Inc. stock logo
Two Sigma Investments LP Trims Position in TG Therapeutics, Inc. (NASDAQ:TGTX)
Two Sigma Investments LP trimmed its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 43.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 606,208 shares of the bio
TG Therapeutics, Inc. stock logo
ProShare Advisors LLC Acquires 12,951 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)
ProShare Advisors LLC increased its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 44.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,955 shares of the biopharmaceu
TG Therapeutics, Inc. stock logo
Captrust Financial Advisors Sells 22,765 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)
Captrust Financial Advisors trimmed its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 75.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,562 shares of the biopharmaceutical company's stock after selling
TG Therapeutics, Inc. stock logo
Castleark Management LLC Increases Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)
Castleark Management LLC lifted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 25.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 211,370 shares of the biopharmaceutical company's stoc
TG Therapeutics, Inc. stock logo
Deutsche Bank AG Has $4.43 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)
Deutsche Bank AG lifted its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 40.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 147,020 shares of the biopharmaceutical company's stock after acquiring an additional 4
TG Therapeutics, Inc. stock logo
Soleus Capital Management L.P. Has $80.71 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)
Soleus Capital Management L.P. raised its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 5.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,681,242 shares
TG Therapeutics, Inc. stock logo
Wexford Capital LP Invests $421,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)
Wexford Capital LP acquired a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 14,000 shares of the biopharmaceutical company's stock, valued at approxima
TG Therapeutics, Inc. stock logo
Nuveen Asset Management LLC Has $54.15 Million Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)
Nuveen Asset Management LLC lowered its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 11.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,798,989 shares of the biopharmaceutical company's
TG Therapeutics, Inc. stock logo
Balyasny Asset Management L.P. Invests $274,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)
Balyasny Asset Management L.P. acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 9,100 shares of the b
TG Therapeutics, Inc. stock logo
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by BNP Paribas Financial Markets
BNP Paribas Financial Markets trimmed its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 49.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,710 shares of the biopharmaceut
TG Therapeutics, Inc. stock logo
TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of "Moderate Buy" by Brokerages
TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy ratin
TG Therapeutics, Inc. stock logo
Rafferty Asset Management LLC Trims Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)
Rafferty Asset Management LLC reduced its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 2.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 331,412 shares of the biopharmaceutica
TG Therapeutics, Inc. stock logo
Gotham Asset Management LLC Sells 64,333 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)
Gotham Asset Management LLC reduced its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 55.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 50,949 shar
TG Therapeutics, Inc. stock logo
Jacobs Levy Equity Management Inc. Has $2.55 Million Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)
Jacobs Levy Equity Management Inc. reduced its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 53.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 84,589 shares of the biopharmaceutic
TG Therapeutics, Inc. stock logo
Nicholas Investment Partners LP Reduces Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)
Nicholas Investment Partners LP trimmed its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 23.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 84,147 shares of the biopharmaceutical company
TG Therapeutics, Inc. stock logo
J. Goldman & Co LP Cuts Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)
J. Goldman & Co LP cut its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 81.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,036 shares of the biopharmaceutical company's stock aft
TG Therapeutics, Inc. stock logo
Integral Health Asset Management LLC Purchases Shares of 150,000 TG Therapeutics, Inc. (NASDAQ:TGTX)
Integral Health Asset Management LLC purchased a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 150,000 shares of the bi
TG Therapeutics, Inc. stock logo
Brevan Howard Capital Management LP Takes $453,000 Position in TG Therapeutics, Inc. (NASDAQ:TGTX)
Brevan Howard Capital Management LP bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 15,042 shares of the biopharmaceutical company's stock, valued at app
TG Therapeutics, Inc. stock logo
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Algert Global LLC
Algert Global LLC lessened its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 52.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 49,061 shares of the biopharmaceutical company's stock after selling 5
TG Therapeutics, Inc. stock logo
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Purchased by Northern Trust Corp
Northern Trust Corp lifted its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 8.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,532,929 shares of the biopharmaceutical company's stock after purcha
TG Therapeutics, Inc. stock logo
Cantor Fitzgerald Predicts TG Therapeutics FY2025 Earnings
TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for shares of TG Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. Cantor Fitzgerald analyst P. Agrawal now forecasts that the bio
TG Therapeutics, Inc. stock logo
Q3 Earnings Forecast for TG Therapeutics Issued By B. Riley
TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Equities researchers at B. Riley upped their Q3 2025 earnings per share estimates for shares of TG Therapeutics in a research note issued to investors on Monday, May 5th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company
TG Therapeutics, Inc. stock logo
B. Riley Brokers Lift Earnings Estimates for TG Therapeutics
TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Equities research analysts at B. Riley boosted their Q2 2025 earnings per share estimates for TG Therapeutics in a research report issued to clients and investors on Monday, May 5th. B. Riley analyst M. Mamtani now expects that the biopharmaceut
TG Therapeutics, Inc. stock logo
Cornerstone Select Advisors LLC Buys Shares of 63,270 TG Therapeutics, Inc. (NASDAQ:TGTX)
Cornerstone Select Advisors LLC purchased a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 63,270 shares of the biopharmaceutical company's stock, va
TG Therapeutics, Inc. stock logo
Lido Advisors LLC Takes $231,000 Position in TG Therapeutics, Inc. (NASDAQ:TGTX)
Lido Advisors LLC bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 7,680 shares of the biopharmaceutical company's stock, valued at approximately $231
J.P. Morgan Remains a Buy on TG Therapeutics (TGTX)
TG Therapeutics, Inc. stock logo
Freestone Grove Partners LP Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)
Freestone Grove Partners LP acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 7,433 shares of the biophar
TG Therapeutics, Inc. stock logo
TG Therapeutics (NASDAQ:TGTX) Shares Gap Down - Here's What Happened
TG Therapeutics (NASDAQ:TGTX) Shares Gap Down - Should You Sell?
TG Therapeutics, Inc. stock logo
TG Therapeutics Target of Unusually High Options Trading (NASDAQ:TGTX)
TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) was the recipient of unusually large options trading on Monday. Investors acquired 8,465 call options on the company. This represents an increase of approximately 46% compared to the average volume of 5,801 call options.
TG Therapeutics, Inc. stock logo
TG Therapeutics (NASDAQ:TGTX) Posts Earnings Results, Misses Expectations By $0.16 EPS
TG Therapeutics (NASDAQ:TGTX - Get Free Report) announced its quarterly earnings data on Monday. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%.
TG Therapeutics, Inc. stock logo
Susquehanna Fundamental Investments LLC Buys Shares of 9,650 TG Therapeutics, Inc. (NASDAQ:TGTX)
Susquehanna Fundamental Investments LLC purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 9,650 share
TG Therapeutics, Inc. stock logo
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Price T Rowe Associates Inc. MD
Price T Rowe Associates Inc. MD lifted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 264.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 297,101 shares of the biopharmaceutical company's stoc
Get TG Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.

TGTX Media Mentions By Week

TGTX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

TGTX
News Sentiment

1.54

1.03

Average
Medical
News Sentiment

TGTX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

TGTX Articles
This Week

11

8

TGTX Articles
Average Week

Get TG Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:TGTX) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners